{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024626","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2023-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.950684+00:00","generated_at":"2026-06-13T08:26:50.902840+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Immix Biopharma enters ATM equity offering agreement with ThinkEquity LLC","bullets":["ATM Sales Agreement with ThinkEquity LLC allows at-the-market sales of common stock, subject to $75M public float limitation.","Commission rate of 3.75% of gross proceeds; company also reimburses legal fees up to $50,000 and quarterly fees.","Sales may occur on Nasdaq Capital Market or other trading markets at prevailing prices; agreement terminable on 10 days' notice.","Prospectus supplement filed July 14, 2023 under effective shelf registration statement (333-269100)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024626","json":"https://secwatch.observer/filing/0001493152-23-024626.json","markdown":"https://secwatch.observer/filing/0001493152-23-024626.md","text":"https://secwatch.observer/filing/0001493152-23-024626.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315223024626/0001493152-23-024626-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315223024626/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:26:50.902840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b81d3b70e92b0ed12afea7c217b61e10b118930f","claim":"Immix Biopharma, Inc. entered into ATM Sales Agreement with ThinkEquity LLC (effective 2023-07-14).","evidence_excerpt":"On July 14, 2023, Immix Biopharma, Inc. (the “Company”) entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1873835/000149315223024626/0001493152-23-024626-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"ThinkEquity LLC"},{"label":"Effective","value":"2023-07-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}